Spain's healthcare system unprepared for rising Alzheimer's cases and new treatments

Spain's healthcare system is bracing for a collision between rising Alzheimer's cases and a medical infrastructure that may not be ready to handle them—or the new treatments beginning to arrive. Two major studies, mapEA and Alma-Care, involving more than 140 experts across Spain's regions, have laid bare the gaps: diagnostic delays stretching to nine months, uneven access to care depending on where you live, and a social safety net with holes large enough to leave patients without resources stranded.

The bottleneck starts early. When someone shows signs of cognitive decline, their primary care doctor can refer them to a specialist relatively quickly—less than three months. But then comes the wait. A first appointment with a hospital neurologist can take six months or longer. By the time a diagnosis is confirmed, nearly a year has passed. This delay matters because early detection and treatment can slow the disease's progression, and the window for intervention is narrow.

Pablo Martínez Lage, scientific director of the CITA-Alzheimer Foundation's research center, identified the root cause with clinical precision: doctors simply don't have enough time in their appointments. The healthcare system is overloaded. Consultations are rushed. The machinery of diagnosis—the cognitive testing, the imaging, the careful listening that neurology demands—gets compressed into slots designed for something faster. Add to this the fact that coordination between primary care doctors and specialists, and between specialists and super-specialists in cognitive decline, remains patchy across the country. Some regions have built efficient networks; others have not. Your postal code, in other words, still determines whether you get timely diagnosis or a long, anxious wait.

The human cost is real and unequal. Jesús Rodrigo, who speaks for patients through the Spanish Alzheimer's Confederation, pointed to a deeper problem: Spain's Dependency Law—the legal framework meant to protect people who need help with daily living—leaves gaps that money fills. If you have savings, you pay out of pocket for the social and healthcare services you need. If you don't, access becomes "seriously limited." This is not a minor inconvenience. For someone with Alzheimer's, it can mean the difference between staying at home with support and having nowhere to turn.

The timing of this crisis is complicated by hope. New treatments for Alzheimer's have been approved by European regulators and show genuine promise in slowing cognitive decline. But they are not panaceas. They work only for patients at certain stages of the disease and with certain biomarkers—a reduced proportion of the total population with Alzheimer's. Still, Rodrigo noted, the number of people who could benefit from these new therapies is larger than the current figure: zero. Spain has not yet deployed these treatments at scale. The system is not ready.

What would readiness look like? It would require more specialized clinics and cognitive decline consultations—the data show these have grown since 2017, which is encouraging. It would require training for primary care doctors and neurologists on how to recognize and manage early cognitive decline. It would require better coordination between the different levels of care so that patients move through the system efficiently rather than getting stuck in waiting rooms. And it would require money. Spain currently spends 0.8 percent of its GDP on social care policies. Peer nations in Europe spend 1 percent. That gap, small as it sounds, translates into real services that don't exist and real people who fall through.

Martínez Lage offered a measured assessment: the situation has improved since the last study in 2017. More specialized units exist. More doctors are paying attention. But inequality persists. Some patients get timely, accurate diagnosis. Others don't—and it depends on where they live. Rodrigo, speaking as an advocate, called the moment "very positive" despite the challenges, pointing toward a more hopeful horizon. The question now is whether Spain's healthcare system can build the infrastructure to meet that horizon before the wave of new cases and new treatments arrives.